afatinib

Afatinib (BIBW 2992) is an irreversible inhibitor of the EGFR family (EGFR-wt, EGFR-L858R, EGFR-L858R/T790M, and HER2) with IC50s of 0.5 nM, 0.4 nM, 10 nM, and 14 nM, respectively.

(R)-Afatinib ((R)-BIBW 2992), an isomer of Afatinib, is a potent, orally administered, irreversible inhibitor targeting the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFR wt, 0.4 nM for EGFR L858R, 10 nM for EGFR L858R/T790M, and 14 nM for HER2, holding potential for research into esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer [1].

Afatinib-D6 is a deuterium-labeled Afatinib. Afatinib (T21312) is an irreversible EGFR family inhibitor.

Afatinib impurity 11 is a byproduct of Afatinib, an irreversible EGFR family inhibitor with IC50 values of 0.5 nM, 0.4 nM, 10 nM, and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M, and HER2, respectively[1].

Afatinib D6 (Standard) is a reference standard of Afatinib D6 intended for quantitative analysis, quality control, and related biochemical research applications. Afatinib D6 (BIBW 2992 D6) is a deuterium-labeled Afatinib. Afatinib is an irreversible EGFR family inhibitor.

Bromo-Afatinib (Afatinibimpurity 95) is an impurity of Afatinib.

Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.

(S)-Afatinib (BIBW2992) is an irreversible EGFR family inhibitor with IC50s of 0.5/0.4/10/14/1 nM for EGFRwt, EGFR (L858R), EGFR (L858R/T790M), HER2, and HER4, respectively.

Afatinib (BIBW 2992) oxalate is an irreversible, orally active bispecific inhibitor of the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFRwt, 0.4 nM for EGFRL858R, 10 nM for EGFRL858R/T790M, and 14 nM for HER2. Afatinib oxalate can be used to study esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.

Afatinib impurity 1 (Afatinib Impurity CSEJXA) is an impurity found in Afatinib.

Afatinib impurity 83 is a contaminant of Afatinib.

Afatinib impurity 34 is an impurity associated with Afatinib.

Afatinib impurity 5 is identified as an impurity of Afatinib.

Afatinibimpurity 32 is an impurity of Afatinib.

Afatinib impurity 102 is a type of Afatinib impurity.

Afatinib Impurity 16 is an impurity associated with Afatinib.

Afatinibimpurity 92 is a type of Afatinib impurity.

Afatinib impurity 4 is an impurity of Afatinib.

Afatinib impurity 2 is a known impurity of Afatinib.

Afatinib impurity 36 is an impurity associated with Afatinib.

Afatinib impurity 33 is an impurity of Afatinib.

Afatinib impurity 17 is an impurity of Afatinib.

Afatinib impurity 58 is a specific impurity of Afatinib.

Afatinib Impurity 9 is a type of Afatinib impurity.